Latest News and Press Releases
Want to stay updated on the latest news?
-
OCALA, Fla., Sept. 20, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company’s drug...
-
佛罗里达州奥卡拉, Sept. 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（美国纽交所股票代码：AIM）今天宣布，已向美国食品药品管理局（FDA）提交一项新药试验前申请（Pre-IND），该试验旨在将Ampligen（安普利近）用作新冠肺炎后认知功能障碍（PCCD）潜在输注疗法的2期临床研究。 ...
-
OCALA, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food...
-
佛羅里達州奧卡拉, Sept. 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) 今天宣佈剛向美國食品藥品監督管理局 (FDA) 提交一項新藥臨床試驗前 (Pre-IND) 申請，以作為 2019 冠狀病毒病後認知功能障礙 (PCCD) 的潛在注射療法。 研究將是一項第 2...
-
OCALA, Fla., Aug. 25, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on the company’s efforts to develop its drug Ampligen as a potential intranasal...
-
OCALA, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update. ...
-
OCALA, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc., the...
-
OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the...
-
OCALA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14,...
-
OCALA, Fla., June 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that all subjects have completed treatment in the Company’s Phase 1 clinical study to assess...